BioSpace News Archive

- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted therapies, such as VMT01, are a promising alternative to current therapies for metastatic melanoma - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy study for the treatment of metastatic mela

The ScreenPro test are administered by our team of trained nurses and provide results in 10 minutes.

The PREDAPT study, sponsored by Cofactor Genomics, is the first multicenter trial which uses Predictive Immune Modeling for cancer therapy decision making.

eMed™, a digital health company democratizing healthcare through digital point-of-care solutions, today announced a partnership with Truepill™, the digital health platform powering consumer health experiences through its diagnostics, telehealth and pharmacy infrastructure.

Intertek, a leading Total Quality Assurance provider to industries worldwide, has been selected as an accredited testing laboratory under the U.S. Food and Drug Administration (FDA) Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program. With this recognition, 12 Medical Centers of Excellence within Intertek’s global network of labs are authorized to assist manufacturers around the world with medical device

Lykan Bioscience, a contract development and manufacturing services organization and provider of the first true end-to-end solution for the manufacture of cell-based therapies, welcomes Kenneth LeClair as Chief Technology Officer.

Ambry Genetics Corporation announced it will be presenting The Uniform Application of Protein Functional Data has an Impressive Potential to Resolve VUS Rates in BRCA2 based on a study published in The American Journal of Human Genetics in collaboration with researchers at the Mayo Clinic, Moffit Cancer, and the University of Utah.

Today, Infinity BiologiX (“IBX”), a next-generation central laboratory, announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) “Genomic Surveillance for SARS-CoV-2 Variants”, to provide genomic sequencing and new variant identification of samples of SARS-CoV-2, the virus that causes COVID-19.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the FDA clearance of the AcQCross™ family of universal transseptal crossing devices.

Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company.